Loading...
•
Mar 31, 2022
Edwards Lifesciences Q1 2022 Earnings Report
Edwards Lifesciences reported first quarter results, demonstrating sales growth and progress in key strategic areas.
Key Takeaways
Edwards Lifesciences reported a 10% increase in sales to $1.34 billion in the first quarter, with underlying sales up 13%. The company reaffirmed its full-year financial guidance and saw growth across all regions and product lines.
Q1 sales grew 10 percent to $1.34 billion; underlying 13 percent
Q1 TAVR sales grew 11 percent; underlying 14 percent
Q1 EPS was $0.59; adjusted EPS was $0.60
Full year 2022 financial guidance unchanged
Edwards Lifesciences
Edwards Lifesciences
Edwards Lifesciences Revenue by Segment
Edwards Lifesciences Revenue by Geographic Location
Revenue by Segment
TAVR Revenue
CapyFin.comTMTT Revenue
CapyFin.comSurgical Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.comEurope Revenue
CapyFin.comJapan Revenue
CapyFin.comRest of World Revenue
CapyFin.com Forward Guidance
The company reaffirmed sales guidance for all product groups. Full year 2022 sales are expected to grow at a low double-digit underlying rate to $5.5 to $6.0 billion, which includes an estimated negative year-over-year impact of $170 million from foreign exchange. Additionally, the company continues to expect full year 2022 adjusted earnings per share of $2.50 to $2.65.
Positive Outlook
- Full year 2022 sales are expected to grow at a low double-digit underlying rate to $5.5 to $6.0 billion.
- The company continues to expect full year 2022 adjusted earnings per share of $2.50 to $2.65, representing mid-teens growth over 2021.
- Company projects total sales to be between $1.36 and $1.44 billion for the second quarter of 2022.
- Company projects adjusted EPS of $0.61 to $0.69 for the second quarter of 2022.
- Confident in long-term strategy and pipeline of innovative therapies.
Challenges Ahead
- Full year 2022 sales includes an estimated negative year-over-year impact of $170 million from foreign exchange.
- Uncertainties associated with the COVID pandemic.
- Risk of clinical trial or commercial results impacting new product approvals and therapy adoption.
- Potential changes to reimbursement for the company's products.
- Impact of currency exchange rates.
Revenue & Expenses
Visualization of income flow from segment revenue to net income